Co‐administration of a GLP‐1 receptor agonist (exenatide) and a SGLT2 inhibitor (dapagliflozin) improved various glycemic variables and cardiovascular risk factors in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy32. Here, SLC5A2 is linked to diabetes mellitus.